Full List Of Stories
Wednesday preview: Brexit, British Land in the spotlight
The market spotlight on Wednesday will shift back towards the Continent and Brexit as leaders from the European Union meet via videoconference.
Europe close: Stocks end on mixed note as investors pause for breath
European shares finished the session on a mixed note as some investors took profits and the euphoria over test results from a second Covid-19 vaccine fizzled out.
US industrial production outstrips forecasts despite drag from oil
Industrial production in the US bounded ahead last month, led by gains in factory and utilities output, even as softness in the oil patch dragged on mining.
US retail sales undershoot forecasts in September and October
US retail sales undershot forecasts in September and October as incomes fell, the mercury dropped and the pandemic strengthened.
Berenberg says StanChart set to resume 'attractive' capital returns, stays at 'buy'
Analysts at Berenberg reiterated their 'buy' recommendation for shares of Standard Chartered, telling clients the lender was now on a path for steady growth from 2022 onwards and to restart returning capital as soon as the following year.
Bank of Georgia posts jump in Q3 profits on wider net interest margins
Bank of Georgia posted slight topline growth over the third quarter as the country's economy rebounded from the initial onslaught of the Covid-19 pandemic.
Intermediate Capital Group reports sharp rise in profits, accelerates fundraisings
Intermediate Capital Group posted a sharp rise in first half profits amid strong demand for its funds and a recovery in portfolio valuations across the period.
Experian posts decline in first half profits despite strong sales in Americas
Experian posted a decline in first half profits despite organic sales growth in the Americas, as the novel coronavirus pandemic hammered other regions.
Sector movers: Rotation into value stocks continues
Investors continued to pick up issues in so-called 'value' sectors at the start of the week, as they were arguably trading at too steep a discount to their estimated fundamental value going forwards given news of another breakthrough in efforts to develop a vaccine against Covid-19.